QuantuMDx Group
QuantuMDx Group is a UK medical device company that develops the Q-POC portable sample-to-answer multiplex PCR diagnostic platform and consumable assays, serving hospitals, clinics, pharmacies, and enterprises through distribution partners including Menarini and Sansure Biotech.
- Company typePrivate
- Founded2008
- HeadquartersNewcastle Upon Tyne, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What QuantuMDx Group does
QuantuMDx Group Limited is a privately held UK medical device company headquartered in Newcastle upon Tyne that develops portable molecular diagnostic platforms for use at the point of care. Founded in 2008, the company builds the Q-POC system, a battery-operated, sample-to-answer multiplex PCR device that compresses a molecular diagnostic laboratory into a single portable instrument and delivers results in approximately 30 minutes for the SARS-CoV-2 assay and 35 minutes for the multiplex respiratory panel (SARS-CoV-2, Flu A/B, RSV). The platform uses lyophilised on-board reagents in sealed single-use cassettes and connects to Laboratory Information Systems via HL7 v3 CDA over Wi-Fi or ethernet (software v3.2). The company is also developing a Capture-XT microfluidic dielectrophoresis platform for sample preparation and cell concentration, and a multiplex STI Plus AMR assay targeting Chlamydia, Gonorrhoeae, Trichomonas, and Mycoplasma with antimicrobial resistance mutation detection.
The company's revenue model combines hardware sales of the Q-POC instrument with recurring consumable revenue from single-use test cassettes, supplemented by licensing and royalty payments from distribution partners. QuantuMDx sells primarily through exclusive channel partners: A.Menarini Diagnostics holds five-year exclusive UK and France rights, and Sansure Biotech holds exclusive China rights under a cooperation agreement that also covers R&D and manufacturing optimization. Direct channels include the UK government via the Public Health England National Microbiology Framework and selective enterprise deployments such as Cignpost Diagnostics for film and TV industry workplace testing. End customers span NHS hospital systems, point-of-care clinics and pharmacies, care homes, sexual health services, and resource-limited settings.
Since January 2020 the company has raised approximately £37 million, including a £16 million UK government grant (March 2020), an £11 million convertible loan with Future Fund participation (March 2021), and a £15 million equity investment from Hong Kong-based Vita Spring IVD Fund (November 2021). It holds CE-IVD marking under IVDR, CTDA approval from the UK Health Security Agency for its SARS-CoV-2 assays, ISO 13485 accreditation, and is included in both lots of the PHE National Microbiology Framework. The company employs 51-100 people and remains in early commercialization with no disclosed revenue.
QuantuMDx Group firmographics
Firmographics- Name
- QuantuMDx Group
- Legal name
- QuantuMDx Group Limited
- Website
- https://quantumdx.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- QuantuMDx Group is a UK medical device company that develops the Q-POC portable sample-to-answer multiplex PCR diagnostic platform and consumable assays, serving hospitals, clinics, pharmacies, and enterprises through distribution partners including Menarini and Sansure Biotech.
- Ownership category
- akta.pro rank
QuantuMDx Group industry classification
Industry- Product category
- Point-of-Care Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where QuantuMDx Group is headquartered
LocationHeadquarters
- HQ city
- Newcastle Upon Tyne
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
QuantuMDx Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Q-POC Hardware Device Sales: Sale of the Q-POC portable PCR analyzer instrument to healthcare facilities, clinics, and enterprises.
- Assay/Reagent Consumables: Recurring sales of single-use test cassettes (SARS-CoV-2, Respiratory Panel, STI assays) for the Q-POC platform.
- Licensing and Royalty Payments: QuantuMDx receives licensing and royalty payments from Sansure for exclusive rights to Q-POC in China.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | No tiered pricing structure publicly disclosed |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
QuantuMDx Group product offering
Product offeringCore offering
QuantuMDx designs, develops, and manufactures the Q-POC portable PCR diagnostic instrument and a menu of single-use test cassettes (assays) for rapid molecular detection of infectious diseases at the point of care. Core products include the Q-POC analyzer, the SARS-CoV-2 detection assay, the SARS-CoV-2/Flu A/B/RSV respiratory panel assay, an STI Plus AMR assay in development, and the Capture-XT microfluidic sample preparation platform in development. Revenue is generated through instrument sales and recurring consumable cassette sales, supplemented by licensing/royalty arrangements with regional partners such as Sansure.
Product overview
QuantuMDx delivers next-generation molecular diagnostics through its Q-POC™ platform and expanding range of assays. The Q-POC™ is a rapid, portable, sample-to-answer multiplex PCR device that compresses an entire molecular diagnostic laboratory into a single device, delivering results in approximately 30 minutes at the point of need. The system comprises a portable analyzer instrument, single-use test cassettes, and sample collection kits. The assay portfolio includes the SARS-CoV-2 detection assay, the SARS-CoV-2/Flu A/B/RSV respiratory panel, and the STI Plus AMR assay (in development). Additionally, Capture-XT is a novel microfluidic sample preparation and cell concentration technology in development using dielectrophoresis.
Differentiator
Problem solved
Functional benefit
Brands
- Q-POC™: A rapid, simple to use, portable, sample-to-answer multiplex PCR device designed for use in hospitals, clinics, pharmacies, and workplaces providing accurate PCR results at the point of need. CE-IVD marked and CTDA approved for SARS-CoV-2 testing.
- CAPTURE-XT
Products and services
- Q-POC Point-of-Care PCR System A rapid, portable, battery-operated, sample-to-answer multiplex PCR diagnostic device that delivers lab-quality molecular diagnostic results in approximately 30 minutes at the point of need. Designed for use by frontline healthcare professionals in hospitals, clinics, pharmacies, and workplaces.
- Q-POC SARS-CoV-2, Flu A/B & RSV Assay A multiplex respiratory panel assay that detects SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) on the Q-POC platform, enabling differential diagnosis and rapid triage in approximately 35 minutes at the point of care.
- Q-POC STI Plus AMR Assay A multiplex assay in development designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, with AMR mutation detection for Neisseria gonorrhoeae and Mycoplasma genitalium to guide targeted antibiotic treatment.
- Capture-XT Sample Preparation Platform A novel microfluidic lab-on-a-chip sample cleanup and cell concentration technology using dielectrophoresis (DEP) to selectively capture and concentrate target particles. Currently in development; preserves cell viability for downstream analysis including culture and molecular testing.
Quantifiable outcome
- 96.9% sensitivity and 98.3% specificity for SARS-CoV-2 detection
- +3 more outcomes
Companies that use QuantuMDx Group
Customer profileNamed customers4 records
Segments6 records
Ideal customer profiles5 records
QuantuMDx Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature6 records
QuantuMDx Group partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, flagship, secondary and supporting.
- A.Menarini Diagnostics S.r.I.corePart of Menarini Pharmaceutical Group (founded 1886, present in 140 countries). Five-year exclusive distribution agreement covering UK and France for Q-POC platform and assays, with potential to expand to other markets.
- Sansure Biotech Inc.flagshipIn-vitro diagnostic solution provider based in Changsha, China (founded 2008). Global R&D, manufacturing and commercial partnership granting Sansure exclusive rights to Q-POC in China. QuantuMDx receives licensing and royalty payments. Also enables component sourcing and manufacturing optimization.
- Cignpost DiagnosticssecondaryLeading provider of COVID-19 workplace testing to UK film and TV industry. Installed Q-POC systems for rapid, onsite PCR testing for cast and crew.
- Cogent TechnologysupportingUK-based manufacturing partner for Q-POC instrument production.
- UnivacsupportingSingapore-based manufacturing partner for Q-POC production.
- St George's, University of LondonsupportingClinical evaluation of Q-POC SARS-CoV-2 assay through DART Study. Published performance data showing 96.9% sensitivity and 98.3% specificity.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
QuantuMDx Group competitors and assessment
Company assessmentDirect peers
- Cepheid (Danaher): Cepheid's GeneXpert system is the dominant rapid PCR platform in hospitals and reference labs globally. It is the most direct benchmark for Q-POC's sample-to-answer molecular diagnostic value proposition, with a much larger installed base and assay menu.
- Abbott (ID NOW): Abbott's ID NOW is a rapid, portable molecular isothermal device used at the point of care. It competes head-to-head with Q-POC in decentralised settings such as urgent care, clinics, and pharmacies for rapid infectious disease diagnostics.
- Visby Medical: Visby Medical produces a single-use, palm-sized PCR device for rapid infectious disease testing (e.g., STI, respiratory). It targets the same decentralised, rapid-PCR point-of-care niche as Q-POC with a more disposable form factor.
- QIAGEN (QIAstat-Dx): QIAstat-Dx is a multiplex sample-to-answer PCR system with syndromic panels, offering comparable time-to-result and ease-of-use positioning to Q-POC in hospital and clinic settings.
- Cue Health: Cue Health offers a connected, cartridge-based rapid molecular diagnostic platform for at-home and point-of-care use. It is a direct competitor in portable PCR/molecular diagnostics aimed at consumer and clinical decentralised testing.
- bioMérieux (BioFire FilmArray): BioFire FilmArray panels deliver multiplex syndromic PCR testing (respiratory, GI, meningitis/encephalitis) in a compact instrument. It overlaps with Q-POC's respiratory and STI multiplex ambitions and competes for hospital POC placements.
- Mesa Labs (Accula, now part of Thermo Fisher): The Accula rapid PCR platform targets point-of-care infectious disease testing (e.g., SARS-CoV-2, Flu A/B, RSV, Strep A). It competes directly with Q-POC in clinic and pharmacy-based POC PCR workflows.
Emerging players
- Binx Health: Binx Health focuses on rapid molecular diagnostics for sexual health (chlamydia/gonorrhoeae at the point of care), with the io system. It is an emerging player addressing the same STI testing market that QuantuMDx's STI Plus AMR assay targets.
- Genedrive: Genedrive is a UK-based molecular diagnostics company developing rapid, near-patient PCR assays (e.g., HCV, neonatal hearing loss, infectious disease). It is a comparable emerging player in portable, point-of-need molecular diagnostics.
Broad incumbents
- Hologic (Panther / Panther Fusion): Hologic's Panther and Panther Fusion systems are high-throughput molecular diagnostic platforms with a broad women's health and infectious disease menu. As a larger incumbent, Hologic competes in the same IVD molecular diagnostics category but focuses on central-lab throughput rather than Q-POC's portability.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
QuantuMDx Group social profiles
Digital presenceQuantuMDx Group compliance and trust
Trust signalCompliance5 records
QuantuMDx Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
QuantuMDx Group leadership team
Management profileNumber of profiles
Profiles10 records
QuantuMDx Group funding detail
Funding detailFunding overview
Funding rounds12 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
QuantuMDx Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about QuantuMDx Group
What does QuantuMDx Group do?
QuantuMDx designs, develops, and manufactures the Q-POC portable PCR diagnostic instrument and a menu of single-use test cassettes (assays) for rapid molecular detection of infectious diseases at the point of care. Core products include the Q-POC analyzer, the SARS-CoV-2 detection assay, the SARS-CoV-2/Flu A/B/RSV respiratory panel assay, an STI Plus AMR assay in development, and the Capture-XT microfluidic sample preparation platform in development. Revenue is generated through instrument sales and recurring consumable cassette sales, supplemented by licensing/royalty arrangements with regional partners such as Sansure.
Is QuantuMDx Group a public or private company?
QuantuMDx Group is a private company. It is classified as venture growth investor backed and is currently operating.
When was QuantuMDx Group founded?
QuantuMDx Group was founded in 2008. It employs 11 to 50 people.
Where is QuantuMDx Group based?
QuantuMDx Group is headquartered in Newcastle Upon Tyne, United Kingdom, in the Europe region.
How does QuantuMDx Group make money?
Three revenue lines are on record. Q-POC Hardware Device Sales are the primary driver. The others are assay/Reagent Consumables and licensing and Royalty Payments.
Who are QuantuMDx Group's main competitors?
Direct peers on record are Cepheid (Danaher), Abbott (ID NOW), Visby Medical, QIAGEN (QIAstat-Dx), Cue Health, bioMérieux (BioFire FilmArray) and Mesa Labs (Accula, now part of Thermo Fisher). Emerging players are Binx Health and Genedrive. Hologic (Panther / Panther Fusion) is listed as a broad incumbent.
Does QuantuMDx Group have an API?
No public API is recorded for QuantuMDx Group.
What industry is QuantuMDx Group in?
QuantuMDx Group's product category is Point-of-Care Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.